Por lo tanto, los GLP-1, aunque potentes, son solo una pieza del rompecabezas en la gestin integral de la obesidad y deben utilizarse como parte de un plan ms amplio de cuidado de la salud
For many compounds, this framework still works
When it gets approved by the right health groups, experts may start giving it to people who need it
The specific criteria for inclusion and exclusion of relevant studies in terms of PI(E)COS (Population, Intervention/Exposure, Comparison, Outcomes, and Study design) are provided in Table 1
Sources FDA FDA Approves New Medication for Chronic Weight Management FDA Wegovy Prescribing Information New England Journal of Medicine Once-Weekly Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Tirzepatide Once Weekly for the Treatment of Obesity CDC Adult Obesity Facts NIDDK Definition & Facts for Adult Overweight & Obesity World Health Organization Obesity: GLP-1 Therapies